Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Financing Activities (2016 - 2025)

Seres Therapeutics' Cash from Financing Activities history spans 11 years, with the latest figure at $61000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 100.06% year-over-year to $61000.0; the TTM value through Sep 2025 reached $3.0 million, up 103.48%, while the annual FY2024 figure was -$90.4 million, 226.03% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $61000.0 at Seres Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $98.0 million in Q3 2022 and bottomed at -$110.9 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $1.4 million (2023), against an average of $6.7 million.
  • The largest annual shift saw Cash from Financing Activities soared 44651.54% in 2023 before it tumbled 7783.37% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$780000.0 in 2021, then skyrocketed by 689.36% to $4.6 million in 2022, then surged by 39.85% to $6.4 million in 2023, then tumbled by 72.98% to $1.7 million in 2024, then plummeted by 96.49% to $61000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Cash from Financing Activities are $61000.0 (Q3 2025), $1.2 million (Q1 2025), and $1.7 million (Q4 2024).